Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Abstract Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-019-0366-x |
id |
doaj-e0ffc782ae1b466aac742bb35c79abaf |
---|---|
record_format |
Article |
spelling |
doaj-e0ffc782ae1b466aac742bb35c79abaf2020-11-25T02:52:59ZengBMCAllergy, Asthma & Clinical Immunology1710-14922019-09-011511510.1186/s13223-019-0366-xEfficacy of add-on mepolizumab in adolescents with severe eosinophilic asthmaSteven W. Yancey0Hector G. Ortega1Oliver N. Keene2Eric S. Bradford3Respiratory Therapeutic Area, GSKRespiratory US Medical Affairs, GSKClinical Statistics, GSKRespiratory Therapeutic Area, GSKAbstract Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU and ≥ 12 years of age in other regions (including the USA), based on a Phase II/III program demonstrating reduced exacerbation rates with 4-weekly treatment. A total of 34 adolescent patients were recruited across the Phase III mepolizumab trials. Consistent with outcomes in the overall population, there was a reduction in the annual rate of clinically significant exacerbations, along with a reduction in blood eosinophil counts in response to mepolizumab in adolescent patients. The safety profile in adolescent patients was consistent with that seen in the overall population. Data from the Phase III clinical development program provide evidence for comparable efficacy and safety of mepolizumab between adolescents with severe eosinophilic asthma and the overall population. Clinical trial registration DREAM, NCT01000506 [MEA112997]; MENSA, NCT01691521 [MEA115588]; SIRIUS, NCT01691508 [MEA115575]; MUSCA, NCT02281318 [200862]; COSMOS, NCT01842607 [MEA115661].http://link.springer.com/article/10.1186/s13223-019-0366-xAdolescentAsthma controlEosinophilsExacerbationsMepolizumabSevere eosinophilic asthma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Steven W. Yancey Hector G. Ortega Oliver N. Keene Eric S. Bradford |
spellingShingle |
Steven W. Yancey Hector G. Ortega Oliver N. Keene Eric S. Bradford Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma Allergy, Asthma & Clinical Immunology Adolescent Asthma control Eosinophils Exacerbations Mepolizumab Severe eosinophilic asthma |
author_facet |
Steven W. Yancey Hector G. Ortega Oliver N. Keene Eric S. Bradford |
author_sort |
Steven W. Yancey |
title |
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma |
title_short |
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma |
title_full |
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma |
title_fullStr |
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma |
title_full_unstemmed |
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma |
title_sort |
efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma |
publisher |
BMC |
series |
Allergy, Asthma & Clinical Immunology |
issn |
1710-1492 |
publishDate |
2019-09-01 |
description |
Abstract Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU and ≥ 12 years of age in other regions (including the USA), based on a Phase II/III program demonstrating reduced exacerbation rates with 4-weekly treatment. A total of 34 adolescent patients were recruited across the Phase III mepolizumab trials. Consistent with outcomes in the overall population, there was a reduction in the annual rate of clinically significant exacerbations, along with a reduction in blood eosinophil counts in response to mepolizumab in adolescent patients. The safety profile in adolescent patients was consistent with that seen in the overall population. Data from the Phase III clinical development program provide evidence for comparable efficacy and safety of mepolizumab between adolescents with severe eosinophilic asthma and the overall population. Clinical trial registration DREAM, NCT01000506 [MEA112997]; MENSA, NCT01691521 [MEA115588]; SIRIUS, NCT01691508 [MEA115575]; MUSCA, NCT02281318 [200862]; COSMOS, NCT01842607 [MEA115661]. |
topic |
Adolescent Asthma control Eosinophils Exacerbations Mepolizumab Severe eosinophilic asthma |
url |
http://link.springer.com/article/10.1186/s13223-019-0366-x |
work_keys_str_mv |
AT stevenwyancey efficacyofaddonmepolizumabinadolescentswithsevereeosinophilicasthma AT hectorgortega efficacyofaddonmepolizumabinadolescentswithsevereeosinophilicasthma AT olivernkeene efficacyofaddonmepolizumabinadolescentswithsevereeosinophilicasthma AT ericsbradford efficacyofaddonmepolizumabinadolescentswithsevereeosinophilicasthma |
_version_ |
1724727407129133056 |